Decision Resources announced today the availability of a new report entitled Deep Vein Thrombosis/Pulmonary Embolism, which finds the market for deep vein thrombosis/pulmonary embolism (DVT/PE) to be poised for significant growth. The report finds that increases in the candidate and drug-treated population; changes in medical practice; and the launch of safer, more effective therapies for both the prevention and treatment of DVT/PE will fuel rapid changes in the market.

(Photo: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION )

"For DVT/PE, the prevention market is almost four times larger than the treatment sector due to the predominantly larger candidate population for preventative therapies," said Jean Paton-Ker, analyst, Decision Resources. "This trend will continue as trials demonstrating the benefit of preventative therapies in an increasing number of patient populations that were previously neglected -- such as moderate-risk surgery and hospitalized patients not undergoing surgery -- are proving that such drugs are a vital component of many surgical and non-surgical procedures."

About the Disease -- Deep Vein Thrombosis

DVT/PE is a major cause of morbidity and mortality in hospitalized patients in the major pharmaceutical markets (the United States, France, Germany, Italy, Spain, United Kingdom, and Japan). Failure to diagnose and administer prophylaxis (preventative therapies) for DVT/PE has made it the most common cause of unexpected death in hospitalized patients (9% of patients die from pulmonary embolism) and a major focus of medical malpractice lawsuits. Awareness of DVT/PE as a life-threatening condition has been enhanced by publicity around deaths from DVT/PE after long-haul flights.

Pharmacor

Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources' on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Deep Vein Thrombosis/Pulmonary Embolism is the latest Cardium program from Pharmacor.

About Decision Resources

Decision Resources, Inc. is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The Company has provided strategic information services for 25 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at http://www.dresources.com/.

All company brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources    781-296-2563    emarshall@dresources.com 

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X37575784

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION

AP Archive: http://photoarchive.ap.org/

PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, +1-781-296-2563,
emarshall@dresources.com

Major Competition Predicted for Pharmaceutical Companies Involved in the Acute Exacerbations of Chronic Bronchitis Market

View Now